Search results
Judge orders detention for man accused of raping disabled woman at Marklund
Daily Herald· 5 days agoA man accused of impregnating a disabled resident of a Marklund home has been ordered held in...
Neurogene shares target cut, retains buy rating By Investing.com
Investing.com· 4 days agoThe analyst anticipates 2024 to be a pivotal year for Neurogene, with significant stock movement...
Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action -...
WFRV 5 Green Bay· 4 days agoLevi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit. CLASS DEFINITION: ...
New gene delivery vehicle shows promise for human brain gene therapy
Science Daily· 1 day agoGene therapy could potentially treat a range of severe genetic brain disorders, which currently have no cures and few treatment options. The enormous challenge of getting therapies past this ...
Short Interest in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Grows By 7.8%
ETF DAILY NEWS· 12 hours agoACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) saw a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 12,030,000 shares ...
Taysha Gene Therapies Inc (TSHA) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
GuruFocus.com via Yahoo Finance· 2 days agoResearch and development expenses increased significantly, from $12.5 million to $20.7 million, driven by higher costs associated with clinical trials and manufacturing activities. The complexity ...
Taysha Gene Therapies’ (TSHA) Buy Rating Reiterated at Jefferies Financial Group
ETF DAILY NEWS· 1 day agoTaysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “buy” rating restated by analysts at Jefferies Financial Group in a research note issued on Tuesday, Benzinga reports. Jefferies ...
ACADIA Pharmaceuticals Q1 2024 Earnings: Solid Growth with New Product Launches
GuruFocus.com via Yahoo Finance· 7 days agoThe company has been pioneering in providing treatments for conditions like Parkinson's disease psychosis with its drug NUPLAZID and recently for Rett syndrome< ...
Neurogene (NASDAQ:NGNE) Price Target Cut to $51.00
ETF DAILY NEWS· 2 days agoNeurogene (NASDAQ:NGNE – Get Free Report) had its target price decreased by equities researchers at HC Wainwright from $55.00 to $51.00 in a note issued to investors on Monday, Benzinga reports ...
Leerink Partnrs Research Analysts Increase Earnings Estimates for ACADIA Pharmaceuticals Inc....
ETF DAILY NEWS· 2 days agoACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) – Research analysts at Leerink Partnrs upped their FY2026 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a ...